Pliant Therapeutics Inc (PLRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $43.21M
Last updated: Nov 17, 2026 at 11:06 AM ET
Pliant Therapeutics Inc (PLRX) Stock Forecast
Analysts expect Pliant Therapeutics (PLRX) to earn -$1.43 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 0 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Sell. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 3.50, inside the Sell band from 3.5 up to 4.5. Sell and Strong Sell make up 25% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 0 | 0.0% |
| Hold | 3 | 75.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 25.0% |
- Consensus
- Sell
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.43
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.28
- EPS consensus
- Next report
- Mar 9, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.43 | -$1.47 to -$1.41 | 3 |
| Dec 31, 2027 | -$1.28 | -$1.47 to -$0.94 | 3 |
Quarterly Estimates
The EPS consensus falls from -$0.38 for the quarter ending Dec 31, 2026 to -$0.39 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.38 | -$0.38 to -$0.38 | 6 |
| Mar 31, 2027 | -$0.39 | -$0.39 to -$0.39 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 2 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.42.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.43 | -$1.46 | -$1.41 | -$1.41 | -$1.42 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.28 | -$1.33 | -$0.81 | -$0.81 | -$1.03 | N/A |
| Quarter ending Mar 31, 2027 | -$0.39 | -$0.39 | -$0.38 | -$0.38 | -$0.39 | N/A |
Frequently Asked Questions About PLRX
What is the PLRX stock forecast?
Consensus analyst estimates put Pliant Therapeutics's EPS at -$1.43 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Sell.
How do analysts rate PLRX stock?
Of 4 analysts covering Pliant Therapeutics, 0 rate it Strong Buy, 0 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Sell.
What EPS do analysts expect from PLRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.43, with estimates from -$1.47 to -$1.41 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.28, with estimates from -$1.47 to -$0.94 from 3 analysts.
How many analysts cover PLRX?
4 analysts rate Pliant Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PLRX pages: Overview, Earnings, Forecast, Financials, Competitors